March 3, 2026
UroGen lands $250M despite $153M loss — Are lenders right to bet on bladder cancer’s next blockbuster?
BioPharma Credit gets a bigger slice — and a $3M fee — as UroGen bets big on ZUSDURI
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
March 3, 2026
Germany Goes to Beijing: What the Merz-Xi summit means for pharma and life sciences
CEO of Leica Microsystems, a Danaher company — one of the few life sciences representatives in a room otherwise dominated by automotive and industrial giants.
February 26, 2026
Three days, three signals: What some of the recent pharma deals and earnings reveal about 2026 strategy
A wave of oncology M&A, targeted mid-cap acquisitions, and cautious earnings guidance suggests pharma is entering a new capital discipline cycle. Here’s what investors should watch.
February 26, 2026
Hikma reports revenue rowth, but stock falls on cautious forecast, amid leadership changes
UK-based Hikma Pharmaceuticals posted higher annual revenue and strong performance in its injectables segment, but investors reacted negatively to its outlook, sending shares to a three-year low.
February 26, 2026
Gilead Sciences buys Arcellx for $7.8B, doubling down on CAR-T oncology strategy
Gilead Sciences has agreed to acquire cancer therapy developer Arcellx Inc. in a transaction valued at up to $7.8 billion, deepening its footprint in cell therapy for blood cancers
February 25, 2026
ELRIG strenghtens scientific and early career leadership as drug discovery network expand
The global drug discovery network ELRIG has appointed Dr Kelly Gray and Dr Elaine Duncan to its Board, reinforcing leadership across scientific programming and early career initiatives,
February 25, 2026
Bispecific ADCs: are dual-target ‘AND-Gate’ designs the future of tumour selectivity?
Antibody-drug conjugates (ADCs) continue to evolve as one of the most promising approaches in targeted cancer therapy, yet the fundamental…
February 25, 2026
Sandoz reports 7% revenue growth in 2025, expands biosimilars and projects stronger 2026 outlook
Sandoz posts 7% revenue growth for 2025, driven by 15% biosimilars expansion, and guides for accelerated sales and margin growth in 2026.
February 24, 2026
Promatix’s lead asset ADC for colorectal cancer has positive preclinical data
Promatix Biosciences presents preclinical data on PBS293-MMAE, a first-in-class bispecific ADC targeting EGFR and EphA2 in colorectal cancer.
February 24, 2026
UBT251 strengthens obesity landscape while CagriSema misses the mark
Novo Nordisk’s mid‑stage “triple G” obesity candidate UBT251 showed up to ~19.7 % mean weight loss in a Chinese phase 2…